A Novel Measurement Concept to Objectively Quantify Severity of Vocal and Speech Related Symptoms Associated With Parkinson's Disease

Status: Completed
Location: See location...
Intervention Type: Device
Study Type: Observational
SUMMARY

The aim of this research program is to develop and validate a smartphone app-based digital measurement concept that: * Objectively quantifies the severity of Parkinson's Disease (PD) related vocal and speech symptoms; * Accurately and sensitively identifies vocal and speech abnormalities associated with the prodromal stage of PD.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 30
Healthy Volunteers: t
View:

• PD:

• Male or female age 30 years or older at Screening Visit.

• Diagnosis of PD as defined by MDS PD diagnostic criteria \[1\]

• PD severity at Screening Visit of either:

‣ PD Hoehn and Yahr Stage 1-2, inclusive (PD Cohort I)

⁃ PD Hoehn and Yahr Stages 3-4, inclusive (PD Cohort II)

• Able and willing to complete all aspects of the study, including at home smartphone app and Zoom telehealth assessments.

• Able to provide informed consent.

• Prodromal PD:

• Confirmation that participant is eligible based on clinician determined predictive criteria of known risk of PD including

∙ Rapid eye movement sleep behavior disorder (RBD), possible, probable or definite, OR

‣ Hyposmia defined as less than 10th percentile on University of Pennsylvania Smell Identification Test (UPSIT), age and gender adjusted, OR

‣ Known genetic variants associated with PD risk, AND Confirmed eligible DAT scan.

• Male or female age 30 or older at Screening Visit.

• Able and willing to complete all aspects of the study, including at home smartphone app and Zoom telehealth assessments

• Able to provide informed consent.

• Age \& Sex Matched Healthy Control:

• Male or female age 30 years or older at Screening visit.

• Able and willing to complete all aspects of the study, including at home smartphone app and Zoom telehealth assessments

• Able to provide informed consent.

Locations
United States
Illinois
Northwestern University
Chicago
Time Frame
Start Date: 2022-09-27
Completion Date: 2025-06-30
Participants
Target number of participants: 91
Treatments
PD Cohort 1
PD patients assessed via the Hoehn \& Yahr (H\&Y) Scale to be in Stages 1-2 of PD (inclusive)
PD Cohort 2
PD patients assessed via the H\&Y Scale to be in Stages 3-4 of PD (inclusive)
Prodromal PD
Patients who meet PI-defined criteria for prodromal PD, i.e., the latent phase of disease progression during which clinical PD symptoms have yet to manifest
Age and Sex-matched Healthy Control
Age \& sex matched healthy control subjects who have not been diagnosed with PD
Related Therapeutic Areas
Sponsors
Collaborators: Koneksa Health, Michael J. Fox Foundation for Parkinson's Research
Leads: Northwestern University

This content was sourced from clinicaltrials.gov